Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 94-101 , January 2010

Kidney Transplantation in Patients With HIV Infection

References 

  1. CDC: Available at: http://www.cdc.gov/hiv/. Accessed June 2, 2009
  2. Naicker S, Han TM, Fabian J. HIV/AIDS–dominant player in chronic kidney disease. Ethn Dis. 2006;16:S256–S260
  3. Kiryluk K, Martino J, Gharavi AG. Genetic susceptibility, HIV infection, and the kidney. Clin J Am Soc Nephrol. 2007;2(suppl 1):S25–S35
  4. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13:1889–1893
  5. Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation. 1998;65:1187–1191
  6. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67:1622–1629
  7. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8:355–365
  8. Tan HP, Kaczorowski DJ, Basu A, et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: A single center preliminary experience. Transplantation. 2004;78:1683–1688
  9. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967–1977
  10. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant. 2001;16:1545–1549
  11. Alonso A, Oliver J. Causes of death and mortality risk factors. Nephrol Dial Transplant. 2004;19(suppl 3):iii8–iii10
  12. Carter JT, Melcher ML, Carlson LL, et al. Thymoglobulin-associated Cd4 + T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006;6:753–760
  13. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet. 2007;370:59–67
  14. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–2831
  15. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905–913
  16. Ubel PA, Arnold RM, Caplan AL. Rationing failure. The ethical lessons of the retransplantation of scarce vital organs. JAMA. 1993;270:2469–2474
  17. Howard RJ. The challenging triangle: Balancing outcomes, transplant numbers and costs. Am J Transplant. 2007;7:2443–2445
  18. Samaniego M, Becker BN, Djamali A. Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol. 2006;2:688–699
  19. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715–2729
  20. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 1994;372:359–362
  21. Ciuffreda D, Pantaleo G, Pascual M. Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation. Transpl Int. 2007;20:649–658
  22. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002;109:681–688
  23. Heredia A, Margolis D, Oldach D, et al. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr. 1999;22:406–407
  24. Coull JJ, Turner D, Melby T, et al. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr. 2001;26:423–434
  25. Sankatsing SU, Jurriaans S, van Swieten P, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS. 2004;18:1925–1931
  26. Selik RM, Byers RH, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002;29:378–387
  27. Swanson SJ, Kirk AD, Ko CW, et al. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: An historical cohort analysis of the United States Renal Data System. Transpl Infect Dis. 2002;4:144–147
  28. Abbott KC, Swanson SJ, Agodoa LY, et al. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol. 2004;15:1633–1639
  29. Stock PG, Roland ME, Hanto DW, et al. Early and unexpected results in a multicenter study of kidney transplantation in HIV-infected recipients. Am J Transplant. 2009;9(suppl 2):197
  30. Locke JE, Montgomery RA, Warren DS, et al. Renal transplant in HIV-positive patients: long-term outcomes and risk factors for graft loss. Arch Surg. 2009;144:83–86
  31. Izzedine H, Launay-Vacher V, Baumelou A, et al. Antiretroviral and immunosuppressive drug-drug interactions: An update. Kidney Int. 2004;66:532–541
  32. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:2816–2820
  33. Bhagani S, Sweny P, Brook G. Guidelines for kidney transplantation in patients with HIV disease. HIV Med. 2006;7:133–139

 Dr Reese is supported by NIH grant K23-DK078688-01.

PII: S1548-5595(09)00163-3

doi: 10.1053/j.ackd.2009.08.004

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 94-101 , January 2010

Article Tools

* Image Usage & Resolution